U.S. SECURITIES AND EXCHANGE COMMISSION
                        Washington, D.C. 20549

                              FORM 10-QSB


(MARK ONE)

     [X]  QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES  EXCHANGE
          ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 1999

     [_]  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
          ACT OF 1934 FOR THE TRANSITION PERIOD FROM ____________ TO ___________


COMMISSION FILE NUMBER:


                       L.O.M. MEDICAL INTERNATIONAL, INC.
        (Exact name of small business issuer as specified in its charter)

<TABLE>
<CAPTION>

<S>                                   <C>                                  <C>
         DELAWARE                                                                       98-0178784
(State or other jurisdiction of      (Primary Standard Industrial          (I.R.S. Employer Identification No.)
 incorporation or organization)       Classification Code Number)
</TABLE>


580-885 Dunsmuir Street, Vancouver, British Columbia, Canada           V6C 1N8
(Address of principal executive offices)                              (Zip Code)

                                 (604) 602-9400
                (Issuer's Telephone Number, including Area Code)



                              Thomas E. Stepp, Jr.
                              Stepp & Beauchamp LLP
                           1301 Dove Street, Suite 460
                         Newport Beach, California 92660
                             Telephone: 949.660.9700
                             Facsimile: 949.660.9010
            (Name, Address and Telephone Number of Agent for Service)


                APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check  whether  the issuer  (1) has filed all  reports  required  to be filed by
Section 13 or 15(d) of the  Exchange  Act during the past 12 months (or for such
shorter period that the  registrant was required to file such reports),  and (2)
has been subject to such filing  requirements  for the past 90 days. [X] Yes [ ]
No

                      APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's classes of common
equity,  as of the latest  practical  date. As of November 30, 1999,  there were
5,589,281  shares of the  issuer's  $.001  par value  common  stock  issued  and
outstanding.


<PAGE>


                         PART I - FINANCIAL INFORMATION

Item 1. Financial Statements


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Balance Sheet
$ United States

For the six months ended November 30, 1999 and 1998
<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------------
                                                                          1999                     1998

-------------------------------------------------------------------------------------------------------
Assets
<S>                                                                <C>                      <C>
Current assets
     Cash                                                          $   329,516              $   440,903
     Accounts receivable                                                23,968                   16,274
     Inventory                                                             100                     --
     Prepaid expenses                                                    3,352                   12,428
-------------------------------------------------------------------------------------------------------
                                                                       356,936                  469,605

Patent costs (note 3)                                                   14,588                  400,445

Capital assets (note 4)                                                 43,730                   40,220

-------------------------------------------------------------------------------------------------------
                                                                   $   415,254              $   910,270
=======================================================================================================

Liabilities and Stockholders' Equity

Current liabilities
     Accounts payable and accrued liabilities                      $    20,016              $    13,770

Redeemable preferred shares (note 5)                                   301,727                  309,677

Minority interest                                                       (5,536)                  (5,536)

Stockholders' equity
     Capital stock (note 6)                                              5,619                    5,508
     Additional paid in capital                                      1,419,961                1,154,635
     Deficit accumulated during the development stage               (1,349,859)                (574,072)
     Accumulated other comprehensive income                             23,326                    6,288
-------------------------------------------------------------------------------------------------------
                                                                        99,047                  592,359

-------------------------------------------------------------------------------------------------------
                                                                   $   415,254              $   910,270
=======================================================================================================
</TABLE>

See accompanying notes to financial statements

On behalf of the Board:

_____________________  Director

_____________________  Director


<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statement of Loss
$ United States

For the six months ended November 30, 1999 and 1998

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------------------------------
                                                      From Inception
                                                     (March 17, 1997)              1999                    1998
                                                   to November 30, 1999
------------------------------------------------------------------------------------------------------------------------------------
<S>                                                     <C>                     <C>                     <C>
Expenses
     Advertising                                        $     8,230             $         5             $     2,365
     Amortization                                            29,778                   8,247                   8,831
     Automotive                                              34,698                   8,187                   7,933
     Consulting fees                                         41,870                  20,981                  10,445
     Design plans                                            10,911                    --                      --
     Director's fees                                         17,141                   1,717                   3,452
     Foreign exchange (gain) loss                            (4,184)                 (1,721)                  3,094
     Insurance                                                1,981                    --                       188
     Interest and bank charges                                4,260                   2,289                     517
     Legal and accounting                                   110,310                  28,331                  21,288
     Licences, fees and dues                                  1,050                     185                     288
     Management fees                                        259,761                  45,248                  35,327
     Office and administration                              111,785                  20,568                  31,875
     Product development                                      1,582                    --                      --
     Promotion and entertainment                             11,634                   1,482                   2,133
     Rent                                                    82,006                  17,717                  16,876
     Repairs and maintenance                                  2,150                    --                        89
     Salaries                                                31,590                  31,590                    --
     Telephone and utilities                                 29,523                   6,312                   6,853
     Travel                                                  25,203                  10,250                   2,396
     Video production                                        20,417                   2,929                   4,958
------------------------------------------------------------------------------------------------------------------------------------
                                                            831,696                 204,317                 158,903
------------------------------------------------------------------------------------------------------------------------------------
Loss from operations                                       (831,696)               (204,317)               (158,903)

Other income
     Interest income                                         44,435                   6,488                  10,806
------------------------------------------------------------------------------------------------------------------------------------
                                                           (787,261)               (197,829)               (148,097)

Write down of inventory (note 8)                             55,734                      --                      --


Write down of product rights and
  patent costs (note 3)                                     374,128                      --                      --


------------------------------------------------------------------------------------------------------------------------------------
Net loss                                                $(1,217,123)            $  (197,829)            $  (148,907)
====================================================================================================================================


Loss per share                                                                  $     (0.03)            $     (0.03)
====================================================================================================================================
</TABLE>

See accompanying notes to financial statements


<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statement of Cash Flows
$ United States

For the six months ended November 30, 1999 and 1998


<TABLE>
<CAPTION>
===================================================================================================================
                                                      From inception
                                                      (March 17, 1997)
                                                   to November 30, 1999            1999                    1998
-------------------------------------------------------------------------------------------------------------------
<S>                                                      <C>                   <C>                   <C>
Operating activities
   Net loss                                              $(1,217,123)          $  (197,829)          $  (148,097)

   Items not involving cash
     Amortization                                             29,778                 8,247                 8,831
     Write down of inventory                                  55,734                  --                    --
     Write down of product rights                            374,128                  --                    --

   Changes in non-cash working capital
     Accounts receivable                                      58,032                 2,474                (4,828)
     Prepaid expenses                                         (3,352)                    1                  (543)
     Accounts payable and accrued liabilities                 (6,208)              (16,388)               (7,534)
     Inventory purchases                                     (55,834)                 --                    --
-------------------------------------------------------------------------------------------------------------------
                                                            (764,845)             (203,495)             (152,171)

Financing
     Issuance of capital stock                               820,580               186,321                80,377
     Issuance of redeemable preferred shares
       of subsidiary                                         309,677                  --                    --

-------------------------------------------------------------------------------------------------------------------
                                                           1,130,257               186,321                80,377

Investing
     Acquisition of capital assets                           (53,787)                 --                 (38,391)
     Acquisition of product rights and patents              (381,292)                   44                 2,891
     Acquisition of shares                                   374,952                  --
-------------------------------------------------------------------------------------------------------------------
                                                             (60,127)                   44               (35,500)


Other comprehensive income                                    24,231                  --

-------------------------------------------------------------------------------------------------------------------
Increase (decrease) in cash                                  329,516               (17,130)             (107,294)

Cash, beginning of period                                       --                 346,646               548,197


-------------------------------------------------------------------------------------------------------------------
Cash, end of year                                        $   329,516           $   329,516           $   440,903
===================================================================================================================
</TABLE>

See accompanying notes to financial statements


<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statement of Stockholders' Equity and Comprehensive Income
$ United States

For the six months ended November 30, 1999 and 1998

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------------------------------
                                                                                           Deficit
                                                                                         Accumulated     Accumulated
                                                   Capital Stock           Additional     During the        Other          Total
                                               Number                       Paid in      Development    Comprehensive  Stockholders'
                                              of Shares       Amount        Capital         Stage          Income          Equity
------------------------------------------------------------------------------------------------------------------------------------
<S>                                           <C>          <C>            <C>            <C>             <C>            <C>
Common shares issued
  net of share issue costs                    5,538,849    $     5,538    $ 1,233,721    $(1,152,030)    $    23,326    $   110,555

Common shares issued
  net of shares issue costs                      50,432             75        166,096             --              --        166,171

Share subscriptions received
  for 6,200 shares at $3.25
  per share                                          --              6         20,144                             --         20,150

Foreign currency translation                         --             --             --             --              --             --

Net loss                                             --             --             --       (197,829)             --       (197,829)

------------------------------------------------------------------------------------------------------------------------------------
Balance, November 30, 1999                    5,589,281    $     5,619    $ 1,419,961    $(1,349,859)    $    23,326    $    99,047
====================================================================================================================================
</TABLE>


<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements
$ United States

For the six months ended November 30, 1999 and 1998
--------------------------------------------------------------------------------

L.O.M.  Medical  International Inc. was incorporated on March 17, 1997 under the
General  Corporation Laws of Delaware.  It conducts  research and development on
new  products  in the  medical  field  and has filed a patent  application  on a
retractable syringe. Operations effectively commenced on June 1, 1997.

1.   Significant accounting policies:

     a)   Going concern

     These  financial  statements have been prepared on the going concern basis,
     which assumes the  realization of assets and  liquidation of liabilities in
     the  normal  course of  business.  As shown in the  consolidated  financial
     statements,  to date, the Company has accumulated a deficit since inception
     of $1,217,123. This factor, among others raises substantial doubt about the
     Company's ability to continue as a going concern.  The Company's ability to
     continue as a going concern is dependent on its ability to generate  future
     profitable  operations  and receive  continued  financial  support from its
     stockholders and other investors.

     b)   Translation of financial statements

     The Company's subsidiary,  L.O.M.  Laboratories Inc. operates in Canada and
     its operations are conducted in Canadian currency.

     The method of translation applied is as follows:

          i)   Assets and  liabilities are translated at the rate of exchange in
               effect at the balance  sheet  date,  being US $1.00 per Cdn $1.45
               ii) Revenues and expenses are  translated at the exchange rate in
               effect at the transaction  date. iii) The net adjustment  arising
               from  the   translation   is   included  in   accumulated   other
               comprehensive income.

     c)   Basis of presentation and consolidation

          The  consolidated  financial  statements  include the  accounts of the
          Company and its 96% owned subsidiary, L.O.M. Laboratories Inc.

     d)   Product rights and patent costs

          Product  rights and patent costs relate to amounts paid to acquire the
          rights  to  produce  and  distribute  products  as well  as the  costs
          associated with patent  applications.  These costs are being amortized
          on a  straight-line  basis over five  years.  Management  periodically
          reviews the carrying values of the product rights and patent costs and
          based upon several  factors,  including the current  assessment of the
          viability  of the  product,  determines  whether  the  carrying  value
          exceeds the net realizable  value for such costs.  If it is determined
          that the carrying  value cannot be  supported,  the related  costs are
          changed  against  operations  in  the  year  of  determination  of the
          impairment in value.


<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements, page 3
$ United States

For the six months ended November 30, 1999 and 1998

--------------------------------------------------------------------------------

1.   Significant accounting policies (continued):

     e)   Capital assets

          Capital  assets are recorded at cost.  Amortization  is provided using
          the following  methods and annual rates which are intended to amortize
          the cost of the assets over their estimated useful life:

================================================================================
         Asset                                    Method                 Rate
--------------------------------------------------------------------------------
         Leasehold improvements            Straight-line                  20%
         Computer software                 Straight-line                 100%
         Equipment                     Declining balance                  30%
         Furniture and fixtures        Declining balance                  20%
--------------------------------------------------------------------------------

     f)   Management estimates

          The  preparation of financial  statements in conformity with generally
          accepted  accounting  principles  in  the  United  States  of  America
          requires  management to make estimates and assumptions that affect the
          reported   amounts  of  assets  and  liabilities  and  disclosures  of
          contingent  assets  and  liabilities  at the  date  of  the  financial
          statements  and the reported  amounts of revenues and expenses  during
          the  reporting   period.   Actual  results  could  differ  from  those
          estimates.

     g)   Financial instruments

          The  fair  values  of the  Company's  cash,  accounts  receivable  and
          accounts payable and accrued  liabilities  approximate  their carrying
          values  due  to  the  relatively  short  periods  to  maturity  of the
          instruments.  It is  not  possible  to  arrive  at a  fair  value  for
          redeemable  preferred  shares as a maturity date is not  determinable.
          The  maximum  credit risk  exposure  for all  financial  assets is the
          carrying amount of those assets.

     h)   Loss per share

     Loss per share has been  calculated  using the weighted  average  number of
     common shares outstanding during the period.

          i)   Accounting standards change

               In June 1998,  the Financial  Accounting  Standards  Board issued
               SFAS no. 133, "Accounting for Derivative  Instruments and Hedging
               Activities." Adoption of this statement is not expected to have a
               significant  impact on the  Company's  results of  operations  or
               financial position.


<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements, page 4
$ United States

For the six months ended November 30, 1999 and 1998

--------------------------------------------------------------------------------
2.   Business combination:

     Effective June 1, 1997, the Company acquired 96% of the outstanding Class A
     common voting shares of L.O.M.  Laboratories  Inc. Prior to and immediately
     after the acquisition, L.O.M. Laboratories Inc. was controlled by a related
     party,   the  president  and   controlling   shareholder  of  the  Company.
     Accordingly,  this  transaction has been measured at the carrying amount of
     the assets and liabilities of L.O.M.  Laboratories Inc. with the difference
     between the carrying amount and the exchange  amount  reflected as a charge
     to equity. Details of the acquisition are as follows:
--------------------------------------------------------------------------------


     Net assets (liabilities) acquired at carrying amounts
       Cash                                                           $ 375,000
       Non-cash current assets                                           82,000
       Product rights and patent costs                                   22,000
       Capital assets                                                    14,000
       Current liabilities                                              (26,224)
       Share subscriptions                                             (605,000)
       Minority interest                                                  5,536
--------------------------------------------------------------------------------
                                                                       (132,688)
       Excess of consideration given over carrying amount
         of net assets acquired                                         132,736
--------------------------------------------------------------------------------
     Consideration given:
       Cash                                                           $      48
================================================================================


3.   Product rights and patent costs:
================================================================================
                                                                        1999

--------------------------------------------------------------------------------
     Product rights                                                   $      --
     Patent costs                                                        14,588
--------------------------------------------------------------------------------
                                                                      $  14,588
================================================================================


     Product rights represent certain rights to manufacture and market a contact
     lens  inserter  and  storage  system  ("Lens-o-matic")   developed  by  the
     president of the Company.

     At the time of the  acquisition of the product rights from the president of
     the Company,  the value  attributed to the product  rights,  $380,885,  was
     agreed to by the Company's  Board of  Directors.  During the year ended May
     31, 1999, the investment was written down to a nominal  amount,  due to its
     speculative nature.

     Patent costs  relate to the costs  incurred  for patent  application  for a
     retractable syringe developed by the Company.



<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements, page 5
$ United States

For the six months ended November 30, 1999 and 1998
======================================================================

4.   Capital assets:
======================================================================
                                                               1999



----------------------------------------------------------------------
                                             Accumulated     Net book
                                  Cost       amortization      value
----------------------------------------------------------------------
     Leasehold improvements      27,919          8,376         19,543
     Computer software              520            455             65
     Equipment                   20,948         11,746          9,202
     Furniture and fixtures      20,746          5,826         14,920

----------------------------------------------------------------------
                                $70,133        $26,403        $43,730
======================================================================



5.   Redeemable preferred shares:

     The Company's  subsidiary has redeemable  preferred  shares  outstanding as
     follows:

<TABLE>
<CAPTION>
======================================================================================================
                                                                                   1999         1998
------------------------------------------------------------------------------------------------------
<S>                                                                               <C>          <C>
     Issued:
         4,000 Class C preferred shares with a par
           value of $100 Cdn redeemable at $110.16 Cdn per share
           at the option of the holder.  Each share is entitled to a fixed
           non-cumulative dividend at the rate of 9% per annum
           payable at such times as determined by the Directors.                  301,727      309,677
======================================================================================================
</TABLE>



<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements, page 6
$ United States

For the six months ended November 30, 1999 and 1998

================================================================================


6.   Capital stock:

     a)   Authorized:

          50,000,000 Common shares with a par value of $.001 each
          5,000,000 Preferred shares with a par value of $.001 each

     b)   Share subscriptions:

          Subsequent  to November  30,  1999,  the Company  issued  6,200 common
          shares at $3.25 per share for net  proceeds  of  $20,144,  which  were
          received prior to November 30, 1999.

     c)   Stock option plan:

          1,000,000  common shares of the Company are reserved for issuance upon
          exercise of stock  options.  As at May 31, 1999, no stock options have
          been granted.

7.   Related party transactions:

          During the year the Company  entered into the  following  transactions
          with related parties:

================================================================================
                                                                           1999
--------------------------------------------------------------------------------


     Legal and accounting fees paid to a director                   $     6,718
     Management fees paid to president                                   60,000
     Office and administration fees paid to president's spouse           18,000
     Office and administration fees paid to an individual
       related to the president                                           8,040
     Rent paid to a company controlled by the president                  17,717



--------------------------------------------------------------------------------
     These  transactions are in the normal course of operations and are measured
     at the exchange  amount of  consideration  established and agreed to by the
     related parties.


<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements, page 7
$ United States

For the six months ended November 30, 1999 and 1998

--------------------------------------------------------------------------------


8.   Commitments:

     The Company is obligated  to make future lease  payments for its offices as
     follows:

         2000                                         $   36,913

         2001                                         $   19,453

         2002                                         $   19,453

         2003                                         $   19,453

         2004                                         $   19,453


9.   Uncertainty due to the Year 2000 Issue:

     The Year 2000 Issue arises because many computerized systems use two digits
     rather than four to identify a year.  Date-sensitive  systems may recognize
     the  year  2000 as 1900  or some  other  date,  resulting  in  errors  when
     information  using  Year 2000  dates is  processed.  In  addition,  similar
     problems  may  arise in some  systems  which use  certain  dates in 1999 to
     represent  something  other than a date. The effects of the Year 2000 Issue
     may be  experienced  before,  on, or after  January  1, 2000,  and,  if not
     addressed,  the impact on operations and financial reporting may range from
     minor errors to significant  systems failure which could affect an entity's
     ability to conduct  normal  business  operations.  It is not possible to be
     certain  that all  aspects of the Year 2000  Issue  affecting  the  entity,
     including  those related to the efforts of customers,  suppliers,  or other
     third parties, will be fully resolved.


Item 2. Management's Discussion and Analysis or Plan of Operation

Development of the Registrant.  L.O.M.  Medical  International  Inc., a Delaware
corporation ("Company"),  was incorporated in the State of Delaware on March 17,
1997.  The  executive  offices of  Registrant  are located at #580-885  Dunsmuir
Street,  Vancouver,  British Columbia,  Canada V6C 1N8.  Registrant's  telephone
number is 604.602.9400.

As a point of clarification,  as used in this Registration  Statement,  the word
"Dollars"  and the  symbol "$" means and  refers to the  currency  of the United
States  of  America,  unless  otherwise  stated.  As used  in this  Registration
Statement,  the term  "CDN$"  means and refers to the  currency  of  Canada,  in
Canadian dollars.

Registrant  was  originally  incorporated  for the  purpose of  researching  and
developing  health  care  products.  The  goal of  Registrant  is to  become  an
innovator and provider of a retractable syringe ("Syringe") and related products
and   technologies  to  the  health  care  market.   Registrant  also  hopes  to
successfully market and distribute its line of eye care products. Registrant has
successfully  patented  and licensed  products in  twenty-four  other  countries
including the United  States and Canada.  Registrant  envisions  that it will be
able to develop new and improved  products and provide the health care  industry
with better, safer products throughout the world.

The  Syringe.  Registrant  anticipates  that the Syringe  will  change  standard
disposal methods for used syringes.  In this regard,  Registrant has developed a
product  designed  to  function  as  a  standard  hypodermic  syringe  with  one
difference:  it is safer and less  perilous  to the  caregiver  or  health  care
worker.  Registrant  believes that the Syringe's unique design will allow health
care providers to avoid direct contact with used needles. The Syringe is covered
by United States Patent No. 5,868,713 dated February 9, 1999, and  international
patents have been filed in 24 different countries.

Once the needle is injected, the user simply has to press the plunger top gently
with his or her thumb to  automatically  retract  the needle into its own sealed
chamber. The needle is now hidden where it remains locked in place and cannot be
used again.  The Syringe does not require a health care worker to use both hands
to retract the needle after it has been used and withdrawn from the patient. The
Syringe  will  be  produced  in  standard  industry  sizes  from  1CC  to 20 CC,
inclusive.  Registrant  anticipates that the products and technologies developed
by Registrant  will be offered to  distributors  on a worldwide  basis,  with an
initial emphasis in Canada and the United States.

Registrant  anticipates  that it will be testing the Syringe in conjunction with
teaching  universities in Canada,  Britain, and other constituents of the United
Kingdom.  Registrant  has  also  developed  ancillary  components  to be used in
medical  emergency  situations  and which can also be used by  hospital  medical
staff and paramedics.

The Lens-O-Matic. Registrant has invented and developed an insertion and storage
device for contact lenses (the "Lens-O-Matic")  which is an ideal medical method
of handling and inserting contact lenses. Registrant has developed the following
components  and  solutions  that  will be used  together  with the  Lens-O-Matic
insertion and storage  system:  (1) a medical  inserter that will remove contact
lenses in a medical  emergency  situation for use by hospital  medical staff and
paramedics; (2) disposable and replacement inserter ends; (3) additional storage
cups and caps;  and (4) all soaking and  disinfecting  solutions  that are to be
used with the Lens-O-Matic inserter.

The Lens-O-Matic is designed so that the practitioner will no longer have direct
hand or  finger  contact  with  the  contact  lens  when  fitting  the  patient.
Registrant  believes that the design of the Lens-O-Matic will reduce the risk of
contamination  and infection to the patient.  Registrant  has developed a liquid
cleaner for the Lens-O-Matic that quickly cleans contact lenses.  Registrant has
obtained  Food and Drug  Administration  Approval  ("FDA") for the  Lens-O-Matic
product.  Registrant  has also  completed  market  testing and believes that the
Lens-O-Matic  was well received at the A.O.A.  convention  in Montreal,  Canada,
where approximately 30,000 units were distributed to opticians, optometrists and
pharmacies.  Registrant has also  completed the  formulation of its contact lens
solutions and copyrights covering


                                       2
<PAGE>


these  products have been  registered.  Registrant has also completed the design
and labeling of the Lens-O-Matic package.  Registrant believes that its eye-care
products are ready for marketing and distribution.

The target markets for the distribution  for the  Lens-O-Matic  product include,
but are not  necessarily  limited  to,  (i)  hospitals  and  clinics,  including
Shippert  Medical  of  Englewood,  Colorado  ("Shippert"),  Cross  Mark  Sales &
Marketing of Plano, Texas; and (ii) optometrists and opticians including, Health
Care Insights of Edison, New Jersey.

The Syringe.  Registrant  anticipates that it will obtain the necessary  plastic
for the injection  molds used to manufacture  the Syringe from various  domestic
and international  suppliers.  Initially,  Tessey Plastics of Elbridge, New York
will be  manufacturing  the Syringe on a contract basis. The engineering for the
molds and dyes are near completion. Registrant also contemplates that it will be
able to readily obtain the necessary packaging for the Syringe.  Registrant does
not believe  that its sales will be affected  by  seasonal  factors.  Registrant
believes  that  prototypes  of the  Syringe  will be ready for testing in March,
2000.  Registrant  believes that it will complete testing in Canada and gain the
necessary regulatory  approvals in or around June, 2000.  Registrant believes it
will complete the necessary United States testing as well as secure the required
United States regulatory approval in or around September, 2000.

As previously  discussed,  Registrant hopes to eventually establish a production
facility  in Spokane,  Washington.  It is  anticipated  that the  facility  will
initially  produce  approximately  2,500,000 units of the Syringe per month with
the capacity to meet increased market demands.  Registrant believes that it will
deliver its products to the North  American  markets by courier.  All supply and
distribution agreements will be negotiated by Health Care Insights.

Once testing of the Syringe is completed, and assuming FDA approval is received,
Registrant hopes to manufacture, or cause to be manufactured, a specified number
of units of the Syringe, which will be provided, at no charge, to a target group
of  physicians  for  testing.  Registrant  plans to  provide  units  to  various
individuals who are to form part of the testing group. These individuals will be
asked to try the Syringe and report their findings. Registrant will then utilize
professionals such as doctors and related health care professionals who approve,
recommend and endorse Registrant's products,  including the Syringe. Thereafter,
Registrant  anticipates  that the Syringe  will be  supplied  to large  national
distributors within specific regions all over the world.  Registrant anticipates
that the distributors will thereafter market the Syringe to pharmacy and medical
supply  companies.   Registrant's   overall  operating  plan  is  to  act  as  a
manufacturer,  selling  directly  and only to  distributors  and retail  chains.
Registrant hopes that the product will gain acceptance in the medical  community
and that  Registrant's  skill in positioning and  merchandising the products and
technology of  Registrant  will enable it to acquire a  commercially  reasonable
portion of the market.

Lens-O-Matic.  Registrant  anticipates  that its eye care  products will be sold
both by  retail  stores  and as a kit  distributed  by the  medical  profession.
Registrant  expects that its eye care products will be sold through  pharmacies,
wholesale drug distributors and chain stores and that such products will be sold
to   Optometrists   and   Ophthalmologists   directly  by   Registrant's   sales
representatives.   Registrant   has  recently   secured  FDA  approval  for  the
manufacturing and distribution of a first product run of its eye-care  products.
We have  developed our own dyes and  injection  molds for our  Lens-O-Matic  and
related  products.  We have paid for all of the dyes and molds and currently own
them. The first product run of our eye care products includes the utilization of
our  production  dyes at full capacity,  the production of a marketable  product
which exceeds FDA standards for medical  devices.  We manufacture  the necessary
components for the Lens-O-Matic  and related  products in Saskatchewan,  Canada.
Registrant  is currently  negotiating  with  Shippert  Medical  Technologies  of
Englewood,  Colorado ("Shippert") pursuant to which Registrant  anticipates that
Shippert  will  distribute  Registrant's  product  line  in the  United  States.
Registrant anticipates that the marketing of its eye-care products will begin in
early 2000.

Registrant plans to focus its initial marketing efforts in Canada and the United
States.  Registrant hopes to eventually  expand its product  marketing and sales
into Europe, South America,  Central America,  Mexico and Asia. Registrant plans
to market its  products by  advertising  in catalogs  and medical  journals,  by
distributing  brochures (both written and video), by direct mail and by posters.
Follow-up  calls will be made to  promising  prospects.  This  approach  will be
Registrant's   primary  marketing  method.  It  is  expected  that  Registrant's
personnel  will attend  various trade shows and medical  conventions in order to
introduce the Syringe with the hope of gaining endorsements and approvals. There
can be no assurance  that  Registrant  would be able to  establish  successfully
other methods of marketing and sales of its


<PAGE>


products  should it become  necessary or desirable in the future.  A significant
portion of Registrant's sales may be made through independent  distributors over
which  Registrant has no control and who also will  represent  products of other
companies.  Registrant recognizes that in order to increase market awareness and
the  marketing  potential of its products,  it must hire adequate  personnel and
institute effective advertising in the most cost effective way.

Registrant is not currently producing commercial  quantities of its products nor
is it currently supplying any services to any third parties. No assurance can be
given that  Registrant,  on a timely basis,  will be able to make the transition
from manufacturing  testing  quantities of the Syringe to commercial  production
quantities  successfully  or be  able to  arrange  for  contract  manufacturing.
Registrant has produced testing quantities  amounting to 33,000 units of its eye
care  products.  Registrant's  current  production  capacity  does allow for the
production of commercial  quantities of its eye care products,  with its present
dyes allowing for the production of 75,000 units per month.  Registrant believes
that this can be  increased  to  150,000  units by  running  additional  shifts.
Registrant  has a second  set of dyes  designed  that will  have a 300,000  unit
capacity  which would allow the  production  for a total of 450,000 units of its
eye care products per month.  Registrant does anticipate that it will be able to
manufacture its products for initial commercialization.

Registrant  anticipates  that it  will  contract  out the  first  two  years  of
production  of the  Syringe.  At  the  end of the  second  year  of  production,
Registrant  anticipates it will engage in significant  discussions regarding the
potential  for the  construction  of its  own  production  facility.  Registrant
recognizes  that  the  construction  of its  own  production  facility  will  be
contingent upon its having reached its sales and profit projections.  Registrant
anticipates  that it will  present this issue for vote by its Board of Directors
and shareholders. In this regard, Registrant anticipates that it will locate its
production facilities in North America,  specifically,  the state of Washington,
due to its  strategic  location  for  penetration  into the  United  States  and
Canadian markets.

As previously  discussed,  Registrant's eye care products are currently produced
in Canada.  Registrant  owns all of the necessary  injection  molds.  Registrant
contracts  out for the  production  of  components  needed for the  assembly and
packaging of its eye care products.  The actual  assembly and packaging are done
by Registrant's own work force.  All other products of Registrant,  those either
currently in production or the subject of future  production will be produced on
a contract  basis through plants that are FDA approved for production of medical
products.

Registrant is currently  negotiating with the Irish Development Board in Ireland
("Development Board").  Representatives from the Development Board have met with
Registrant's  Board of  Directors on 3 different  occasions  and have offered to
assist Registrant in establishing a production  facility in Ireland.  Registrant
has already sent  representatives  to Ireland to discuss the  production  of the
Syringe  as  well  as  strategic   alliances  for  market  distribution  of  all
Registrant's products. Registrant's plans to construct a production facility are
merely  preliminary.  As such,  Registrant  has not reached an estimation of the
capital resources necessary to fund such a project nor has Registrant determined
how long such a project would take to complete.  Registrant  anticipates that at
the end of the  projected  two-year  period,  Registrant  will have a sufficient
revenue stream to finance, at least partially,  the construction of the proposed
production  facilities.  However, there can be no assurance that Registrant will
have the  necessary  funds at the end of the two-year  period to  construct  its
proposed production facilities.  Should Registrant not have the necessary funds,
Registrant  anticipates it will continue to cause its products to be produced on
a contract basis.

Currently,  Registrant does have the necessary production  facilities to produce
its line of eye care products on a commercial basis. Registrant has FDA approval
to  market  its  line of eye  care  products  in the  United  States.  Also,  as
previously  discussed,  Registrant has the necessary Canadian approval to market
its eye-care products in Canada. Shippert Medical will be marketing Registrant's
eye care  products  in the United  States as well as in Canada.  Registrant  has
entered into a marketing and distribution  contract with Shippert  Medical.  The
contract has an initial two-year term with a two-year renewal option.

Business of Registrant's Subsidiary. On or about June 1, 1997, Registrant agreed
to purchase  4,800 of the 5,000 total  issued and  outstanding  shares of L.O.M.
Laboratories Inc.'s ("L.O.M.  Laboratories") Class "A" common shares. Registrant
agreed to pay  US$1.00  per share.  This  represents  a 96%  interest  in L.O.M.
Laboratories.  L.O.M.  Laboratories owned the rights to the Lens-O-Matic  system
until January 1, 1998, when Registrant purchased those


                                       4
<PAGE>


rights for  US$380,885.  The primary  business  purpose of the  subsidiary is to
develop and market new products through Registrant.

Liquidity. The Registrant had cash resources of US$440,903 at November 30, 1998.
At November 30, 1999, the Registrant  had cash  resources of  US$329,516.00.  At
November 30, 1999, the Registrant had total current assets of US$356,936.00  and
total current  liabilities of US$20,016.00.  At November 30, 1999, total current
assets  exceeded  total  current  liabilities  by  US$336,920.00.  The  cash and
equivalents  constitute the Registrant's  present internal sources of liquidity.
Because neither the Registrant nor its subsidiary are generating any significant
revenues,  the Registrant's only external source of liquidity is the sale of its
capital stock.

Results of  Operations.  The  Registrant  has not yet realized  any  significant
revenue from operations. Loss from operations from March 17, 1997 (inception) to
November  30, 1999,  was  US$1,217,123.00.  The net loss for the 3-month  period
ended November 30, 1998 was  US$148,097.00.  The net loss for the 3-month period
ended  November 30, 1999,  was  US$197,829.00.  Such losses were  primarily  the
result of selling,  general and administrative  expenses,  management fees, rent
and consulting fees.

The Registrant may require additional cash to implement its business strategies,
including cash for (i) payment of increased  operating expenses and (ii) further
implementation of those business strategies. No assurance can be given, however,
that the Registrant  will have access to the capital  markets in the future,  or
that  financing  will be  available  on  acceptable  terms to  satisfy  the cash
requirements  of the  Registrant  to  implement  its  business  strategies.  The
inability of the Registrant to access the capital  markets or obtain  acceptable
financing could have a material  adverse effect on the results of operations and
financial conditions of the Registrant.

The  Registrant's  forecast of the period of time  through  which its  financial
resources  will be  adequate  to support  its  operations  is a  forward-looking
statement that involves risks and  uncertainties,  and actual results could vary
as a result of a number of factors.

The Registrant  anticipates that it will need to raise additional capital within
the next 12 months in order to  develop,  promote,  produce and  distribute  its
proposed  products.  Such  additional  capital may be raised through  additional
public or private financings,  as well as borrowings and other resources. To the
extent  that  additional  capital  is  raised  through  the  sale of  equity  or
equity-related  securities,  the  issuance of such  securities  could  result in
dilution  of the  Registrant's  stockholders.  There  can be no  assurance  that
additional  funding will be available on favorable terms, if at all. If adequate
funds  are not  available  within  the next 12  months,  the  Registrant  may be
required to curtail its  operations  significantly  or to obtain  funds  through
entering  into  arrangements  with  collaborative  partners  or others  that may
require the Registrant to relinquish  rights to certain of its products that the
Registrant would not otherwise relinquish.

Registrant,  being  a  developmental  stage  enterprise,  is  currently  putting
technology in place which will, if successful, mitigate the net loss experienced
by Registrant.  Registrant is reviewing its options to raise substantial  equity
capital.  Management has proceeded as planned in the ongoing  development of the
Syringe and the Lens-O-Matic.  In order to meet its requisite budget, management
has held and continues to conduct  negotiations  with investors.  Registrant has
also  conducted  extensive  negotiations  with various  medical  companies in an
attempt to establish beneficial strategic alliances. Registrant hopes that these
negotiations  will result in significant  investment  income for Registrant.  To
achieve and maintain the  competitiveness  of its products and to conduct costly
and time-consuming research and development, Registrant may be required to raise
substantial  funds in addition to the funds already  raised through the issuance
of  Registrant's  shares.  Registrant's  forecast for the period of time through
which its financial  resources  will be adequate to support its  operations is a
forward-looking  statement  that involves  risks and  uncertainties,  and actual
results  could fail as a result of a number of factors.  Registrant  anticipates
that it will need to raise  additional  capital  in order to  develop,  promote,
produce and  distribute  its  products.  Such  additional  capital may be raised
through additional public or private financings, as well as borrowings and other
resources.

There can be no  assurance  that  additional  funding  will be  available  under
favorable terms, if at all. If adequate funds are not available,  Registrant may
be required  to curtail  operations  significantly  or to obtain  funds  through
entering  into  arrangements  with  collaborative  partners  or others  that may
require Registrant to relinquish rights to certain products


                                       5
<PAGE>


that Registrant would not otherwise  relinquish.  However,  Registrant  believes
that it is poised to maintain its long-term liquidity.  Management of Registrant
believes that its plans  described  above will enable it to meet its obligations
for a period of at least twelve (12) months from  November 30, 1999.  Registrant
believes  that within a short  period of time,  it can begin  manufacturing  and
marketing  commercial  quantities  of its eye care  products.  Coupled  with the
further  issuance  of common  stock of  Registrant,  Registrant  believes it can
significantly improve its long-term liquidity.

The Registrant does not anticipate any material  expenditures within the next 12
months.  The  Registrant  does  not  anticipate  any  significant  research  and
development within the next 12 months,  nor does the Registrant  anticipate that
it will lease or purchase any significant  equipment  within the next 12 months.
The  Registrant  does not  anticipate a significant  change in the number of its
employees within the next 12 months.

Item 3. Defaults Upon Senior Securities

None

Item 4. Submission of Matters to Vote of Security Holders

None

Item 5. Other Information

None

Item 6. Exhibits and Reports on Form 8-K

None


                                       6
<PAGE>


                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.

Dated:   February 17, 2000                  L.O.M. Medical International, Inc.


                                            By:/s/ John Klippenstein
                                               -----------------------
                                                     John Klippenstein
                                            Its:     President


                                       7